| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID1625: Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma |
|
Medicine details |
|
| Medicine name | cabozantinib (Cabometyx®) |
| Formulation | 20 mg, 40 mg , 60 mg film coated tablets |
| Reference number | 4843 |
| Indication | In combination with nivolumab for the first-line treatment of advanced renal cell carcinoma in adults |
| Company | Ipsen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/03/2021 |
| NICE guidance | ID1625: Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma |